Immune responses in the mammalian inner ear and their implications for AAV-mediated inner ear gene therapy
Hearing Research, ISSN: 0378-5955, Vol: 432, Page: 108735
2023
- 9Citations
- 13Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef7
- Captures13
- Readers13
- 13
- Mentions1
- News Mentions1
- News1
Most Recent News
Studies from National Institutes of Health (NIH) Add New Findings in the Area of Gene Therapy (Immune Responses In the Mammalian Inner Ear and Their Implications for Aav-me Diate D Inner Ear Gene Therapy)
2023 MAY 11 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Daily News -- Investigators discuss new findings in Biotechnology - Gene
Review Description
Adeno-associated virus (AAV)-mediated inner ear gene therapy is a promising treatment option for hearing loss and dizziness. Several studies have shown that AAV-mediated inner ear gene therapy can be applied to various mouse models of hereditary hearing loss to improve their auditory function. Despite the increase in AAV-based animal and clinical studies aiming to rescue auditory and vestibular functions, little is currently known about the host immune responses to AAV in the mammalian inner ear. It has been reported that the host immune response plays an important role in the safety and efficacy of viral-mediated gene therapy. Therefore, in order for AAV-mediated gene therapy to be successfully and safely translated into patients with hearing loss and dizziness, a better understanding of the host immune responses to AAV in the inner ear is critical. In this review, we summarize the current knowledge on host immune responses to AAV-mediated gene therapy in the mammalian inner ear and other organ systems. We also outline the areas of research that are critical for ensuring the safety and efficacy of AAV-mediated inner ear gene therapy in future clinical and translational studies.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0378595523000473; http://dx.doi.org/10.1016/j.heares.2023.108735; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85150769028&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36965335; https://linkinghub.elsevier.com/retrieve/pii/S0378595523000473; https://dx.doi.org/10.1016/j.heares.2023.108735
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know